Disc Medicine, Inc. (IRON)
(Delayed Data from NSDQ)
$58.03 USD
+0.96 (1.68%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $58.01 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IRON 58.03 +0.96(1.68%)
Will IRON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRON
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
IRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for IRON
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight
Disc Medicine (IRON) Receives a Buy from TD Cowen
Disc Medicine GAAP EPS of -$1.58
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update | IRON ...
Disc Medicine reports Q2 EPS ($1.58), consensus ($1.14)